Publication date: Jul 09, 2025
These results position delpazolid as a promising alternative to linezolid for future TB treatment regimens-pending confirmation in larger studies. PD Dr. Norbert HeinrichBoth sutezolid and delpazolid are members of the oxazolidinone class, like linezolid, but are less toxic for patients. However, linezolid is problematic for patients as it shows significant toxicity. A once-daily dose of 1200 mg achieved the desired drug levels for maximum efficacy and was well tolerated over 16 weeks. She says: ‘These findings are encouraging and show there is hope for better drugs for drug-resistant TB. The findings were published on 7 July in two peer-reviewed articles in The Lancet Infectious Diseases, one of the world’s leading journals in the field of infectious disease medicine. Importantly, no cases of nerve damage or blood-related side effects were observed at this dose.
| Concepts | Keywords |
|---|---|
| African | Activity |
| Antibiotic | Combination |
| July | Delpazolid |
| Munich | Dose |
| Drug | |
| Drugs | |
| Findings | |
| Infectious | |
| Linezolid | |
| Panacea | |
| Patients | |
| Resistant | |
| Sutezolid | |
| Tb | |
| Treatment |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Moxifloxacin |
| drug | DRUGBANK | Spinosad |
| drug | DRUGBANK | Delamanid |
| disease | IDO | blood |
| disease | MESH | Tuberculosis |
| pathway | KEGG | Tuberculosis |
| disease | IDO | role |
| drug | DRUGBANK | Pretomanid |
| drug | DRUGBANK | Bedaquiline |
| disease | MESH | Infection |
| disease | IDO | infectious disease |
| pathway | REACTOME | Infectious disease |
| drug | DRUGBANK | Linezolid |
| drug | DRUGBANK | Sutezolid |
| drug | DRUGBANK | Tropicamide |
| disease | MESH | Infectious Diseases |